Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of VNRX-9945 in Healthy Volunteers
NCT04845321Phase 1Terminated
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing VNRX-9945 with Placebo (2 arms). Primary endpoint: Number of subjects with adverse events. Started Jun 2021; status: terminated.
02
Drugs
VNRX-9945
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04845321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845321.